ABT-239 NEW
| Price | $39 | $89 | $143 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: ABT-239 | CAS No.: 460746-46-7 |
| Purity: 99.94% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | ABT-239 |
| Description | ABT-239 is a novel, highly efficacious non-imidazole class histamine H3 receptor (H3R) antagonist and also acts as a transient receptor potential vanilloid type 1 (TRPV1) antagonist. |
| In vitro | Perfusing the tuberomammillary nucleus (TMN) with ABT-239 selectively activates c-Fos in the nucleus basalis of Meynert (NBM) and cortex. Moreover, when the TMN is perfused with ABT-239 at a concentration of 10 μM, there is an increase in histamine release from the TMN, NBM, and cortex; however, this effect is not observed in either the striatum or the nucleus accumbens (NAcc). |
| In vivo | ABT-239, administered intraperitoneally (i.p.) at a dosage of 3 mg/kg, markedly delays seizure onset, diminishes behavioral seizures triggered by KA, and lowers the occurrence of head bobbing and forelimb clonus in mice. Additionally, at this dosage, ABT-239 enhances memory by converting a short-term learning event into a long-lasting memory in wild type (WT) mice, albeit not in those lacking histamine. The compound is also found to significantly reduce all stages of neuronal damage. In conjunction, ABT-239 and TDZD-8 (10 mg/kg, i.p.) notably decrease the quantity of pyknotic neurons in the hippocampi of mice. When ABT-239 (1 mg/kg, i.p.) is combined with a sub-therapeutic dose of SVP (150 mg/kg, i.p.), there is a marked decrease in behaviors associated with distress such as immobility, head bobbing, and forelimb clonus. A higher dose combination of ABT-239 and TDZD-8 exhibits the most significant enhancement of Bcl-2 expression and reduction in Bax levels, indicating improved neuronal survival. Additionally, combined administration of ABT-239 (at doses of 1 and 3 mg/kg, i.p.) with nicotine enhances nicotine's beneficial effects on memory acquisition and consolidation, with further improvements observed at lower concentrations of ABT-239 (0.1 mg/kg, i.p.) and nicotine. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 90 mg/mL (272.38 mM), Sonication is recommended. H2O : insoluble 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (9.99 mM), Sonication is recommended. |
| Keywords | TRPVChannel | TRPV1 | TRPV Channel | TRPChannel | TRP Channel | ABT-239 | ABT239 | ABT 239 |
| Inhibitors Related | Undecane | Rosiglitazone | Caffeic Acid | Meclizine dihydrochloride | Famotidine | Probenecid | 1,4-Cineole | Sodium butanoate | trans-Cinnamaldehyde | Alginic acid | Mianserin hydrochloride | Trazodone hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | GPCR Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY